Source: DGNews | Posted 9 years ago
Multiple Sclerosis Patients On Rebif (Interferon Beta-1a) More Likely To Remain Relapse Free Than Patients On Avonex At 48 Weeks
Tags:
Head-To-Head Study of Interferon Beta-1A Treatments Published In Neurology
GENEVA, ROCKLAND, MA and NEW YORK, NY -- November 26, 2002 -- Serono, S.A. (virt-x: SEO and NYSE: SRA) and Pfizer Inc (NYSE: PFE) Serono's multiple sclerosis therapy, Rebif
Comments